(VIANEWS) – KITRON (KIT.OL), ABN AMRO BANK N.V. (ABN.AS), MEDISTIM (MEDI.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. KITRON (KIT.OL)
38% sales growth and 24.07% return on equity
Kitron ASA operates as an electronics manufacturing services company in Norway, Sweden, rest of Europe, the United States, and internationally. It manufactures electronics that are embedded in the customers' products; and box-built electronic products. The company's services include development services, such as product development, product management, and re-engineering services; and industrialization services, including prototype manufacturing, evaluation of new products, component engineering and database, test development, design and build of high level assembly lines, and environmental durability testing. Its services also comprise sourcing and procurement services; manufacturing, assembling, and testing of electronic products for the professional market; redesign, repair, and maintenance; and logistics and distribution services. The company was incorporated in 1996 and is headquartered in Billingstad, Norway.
Earnings Per Share
As for profitability, KITRON has a trailing twelve months EPS of kr2.23.
PE Ratio
KITRON has a trailing twelve months price to earnings ratio of 20.13. Meaning, the purchaser of the share is investing kr20.13 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.07%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
KITRON’s EBITDA is 14.47.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on May 2, 2023, the estimated forward annual dividend rate is 0.5 and the estimated forward annual dividend yield is 1.08%.
Moving Average
KITRON’s worth is way above its 50-day moving average of kr39.47 and way above its 200-day moving average of kr28.28.
Yearly Top and Bottom Value
KITRON’s stock is valued at kr44.90 at 02:20 EST, under its 52-week high of kr47.20 and way higher than its 52-week low of kr17.26.
More news about KITRON.
2. ABN AMRO BANK N.V. (ABN.AS)
19.6% sales growth and 9.3% return on equity
ABN AMRO Bank N.V. provides various banking products and services to retail, private, and business clients in the Netherlands and internationally. It operates through three segments: Personal & Business Banking, Wealth Management, and Corporate Banking. The company provides savings and deposits products; labelled residential mortgage products under the Florius brands; and consumer loans under the Alpha Credit Nederland, Credivance, Defam, Moneyou, and ABN AMRO brands. It also issues, promotes, manages, and processes credit cards; provides revolving credit card facilities and pension schemes, as well as consumer credit and mortgages; and life and non-life insurance products. In addition, it offers asset-based solutions, including working capital solutions, equipment leases and loans, and vendor lease services; private banking and wealth-management-related services; and derivatives and equity clearing services. ABN AMRO Bank N.V. was incorporated in 2009 and is headquartered in Amsterdam, the Netherlands.
Earnings Per Share
As for profitability, ABN AMRO BANK N.V. has a trailing twelve months EPS of €2.23.
PE Ratio
ABN AMRO BANK N.V. has a trailing twelve months price to earnings ratio of 6.27. Meaning, the purchaser of the share is investing €6.27 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.3%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is 18% and a drop 30% for the next.
Volume
Today’s last reported volume for ABN AMRO BANK N.V. is 584853 which is 82.89% below its average volume of 3419290.
Moving Average
ABN AMRO BANK N.V.’s value is below its 50-day moving average of €14.52 and above its 200-day moving average of €12.98.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Apr 21, 2023, the estimated forward annual dividend rate is 1.6 and the estimated forward annual dividend yield is 11.76%.
More news about ABN AMRO BANK N.V..
3. MEDISTIM (MEDI.OL)
16.7% sales growth and 31.89% return on equity
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, it distributes and sells third party medical equipment. The company was incorporated in 1984 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, MEDISTIM has a trailing twelve months EPS of kr6.39.
PE Ratio
MEDISTIM has a trailing twelve months price to earnings ratio of 41.16. Meaning, the purchaser of the share is investing kr41.16 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 31.89%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Apr 25, 2023, the estimated forward annual dividend rate is 4.5 and the estimated forward annual dividend yield is 1.7%.
Sales Growth
MEDISTIM’s sales growth is 15.7% for the ongoing quarter and 16.7% for the next.
More news about MEDISTIM.
4. BOUYGUES (EN.PA)
16.5% sales growth and 8.4% return on equity
Bouygues SA, together with its subsidiaries, operates in the construction, energy, telecom, and media sectors in France and internationally. The company designs, builds, renovates, operates, and deconstructs building, infrastructure, and industrial projects; develops urban planning, residential, and commercial projects; builds and maintains roads and motorways, airport runways, ports, industrial logistics hubs, external works and amenities, reserved-lane public transport, recreational facilities, and environmental projects, as well as undertakes civil engineering, road safety, and signaling activities; produces, distributes, sells, and recycles aggregates, emulsions, asphalt mixes, ready-mix concrete, and bitumen; construction, renewal, and maintenance of rail networks; and installation and maintenance of pipes and pipelines. It also produces TF1, TMC, TFX, TF1, and LCI complementary TV channels; operates TV Breizh, Histoire TV, Ushuaïa TV and Serieclub channels; produces, broadcasts, and distributes content; operates la seine musicale entertainment and concert venue; produces cinemas; and entertainment and leisure comprising licenses and publishes boards games, as well as music production and live events. Further, it offers telecom services; mobile and fixed network services; and Bbox Fibre, an internet box. Additionally, the company provides design, installation, and maintenance services in various fields that include cooling and fire protection, facility management, digital and ICT, electrical, and mechanical and robotics, as well as heating, ventilation, and air conditioning. The company was founded in 1952 and is based in Paris, France.
Earnings Per Share
As for profitability, BOUYGUES has a trailing twelve months EPS of €2.57.
PE Ratio
BOUYGUES has a trailing twelve months price to earnings ratio of 11.77. Meaning, the purchaser of the share is investing €11.77 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.4%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
BOUYGUES’s EBITDA is 11.02.
Volume
Today’s last reported volume for BOUYGUES is 200607 which is 83.09% below its average volume of 1186410.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 15.3% and 14.7%, respectively.
Moving Average
BOUYGUES’s worth is under its 50-day moving average of €31.44 and higher than its 200-day moving average of €30.00.
More news about BOUYGUES.
5. TIPIAK (TIPI.PA)
13.7% sales growth and 6.82% return on equity
Tipiak Société Anonyme, a food company, manufactures prepared food products, frozen ready-meals, pastry products, groceries, and crusty bread products. The company offers groceries, such as breadcrumbs, cereals, couscous, croutons, Japanese pearls, potato starch, quinoa, and tapioca; frozen products, including savory products, appetizers, and side dishes with grains; and frozen sweet products comprising macarons, mini eclairs, and petits fours. It sells its products in France, England, and the United States. The company was founded in 1830 and is based in Saint-Aignan-Grandlieu, France.
Earnings Per Share
As for profitability, TIPIAK has a trailing twelve months EPS of €3.7.
PE Ratio
TIPIAK has a trailing twelve months price to earnings ratio of 16.49. Meaning, the purchaser of the share is investing €16.49 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.82%.
Sales Growth
TIPIAK’s sales growth is 13.7% for the present quarter and 13.7% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 12.9%, now sitting on 239.37M for the twelve trailing months.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jul 4, 2023, the estimated forward annual dividend rate is 1.65 and the estimated forward annual dividend yield is 2.8%.
Moving Average
TIPIAK’s value is above its 50-day moving average of €59.56 and higher than its 200-day moving average of €58.28.
More news about TIPIAK.
6. LERØY SEAFOOD GP (LSG.OL)
10.7% sales growth and 15.65% return on equity
Lerøy Seafood Group ASA produces, processes, markets, sells, and distributes seafood products worldwide. It operates in three segments: Wildcatch; Farming; and Value-Added Processing, Sales and Distribution. The company offers smoked and gravad salmon, and trout products; farmed and wild catch whole fishes; fillets and portions; ready-to-eat and ready-to-cook products; fish blocks and cubes; breaded products; pre-fried fish burgers and patties; crustaceans and molluscs; seaweeds; and other products. Lerøy Seafood Group ASA markets its products primarily under the Norway Seafoods, Arctic Supreme, Fjord trout, Aurora Salmon, Fossen, Sea Eagle, Lerøy, and M?r brands to shops, restaurants, canteens, and hotels. The company was founded in 1899 and is headquartered in Bergen, Norway. Lerøy Seafood Group ASA is a subsidiary of Austevoll Seafood ASA.
Earnings Per Share
As for profitability, LERØY SEAFOOD GP has a trailing twelve months EPS of kr5.17.
PE Ratio
LERØY SEAFOOD GP has a trailing twelve months price to earnings ratio of 9.18. Meaning, the purchaser of the share is investing kr9.18 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.65%.
Yearly Top and Bottom Value
LERØY SEAFOOD GP’s stock is valued at kr47.48 at 02:20 EST, way below its 52-week high of kr76.40 and way higher than its 52-week low of kr38.40.
More news about LERØY SEAFOOD GP.
7. NORWEGIAN AIR SHUT (NAS.OL)
10.5% sales growth and 26.91% return on equity
Norwegian Air Shuttle ASA, together with its subsidiaries, provides air travel services in Norway and internationally. It operates short haul point to point domestic and cross border flights services. It is also involved in aircraft financing, leasing, and ownership activities; and cargo activities. It operates a fleet of 70 aircrafts. Norwegian Air Shuttle ASA was founded in 1993 and is headquartered in Fornebu, Norway.
Earnings Per Share
As for profitability, NORWEGIAN AIR SHUT has a trailing twelve months EPS of kr0.95.
PE Ratio
NORWEGIAN AIR SHUT has a trailing twelve months price to earnings ratio of 13.07. Meaning, the purchaser of the share is investing kr13.07 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 26.91%.
Moving Average
NORWEGIAN AIR SHUT’s worth is way above its 50-day moving average of kr10.95 and way above its 200-day moving average of kr9.25.
Yearly Top and Bottom Value
NORWEGIAN AIR SHUT’s stock is valued at kr12.41 at 02:20 EST, below its 52-week high of kr13.53 and way above its 52-week low of kr6.33.
Earnings Before Interest, Taxes, Depreciation, and Amortization
NORWEGIAN AIR SHUT’s EBITDA is 0.73.
More news about NORWEGIAN AIR SHUT.
8. NAVAMEDIC (NAVA.OL)
9.6% sales growth and 22.97% return on equity
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, obesity, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr1.78.
PE Ratio
NAVAMEDIC has a trailing twelve months price to earnings ratio of 22.13. Meaning, the purchaser of the share is investing kr22.13 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.97%.
More news about NAVAMEDIC.
